A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1	2025-04-16		NCT03952078

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Corvus Pharmaceuticals, Inc.	4

22 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	1
Beijing Boren Hospital	Beijing	China	1
Beijing Cancer Hospital	Beijing	China	208
Beijing Friendship Hospital	Beijing	China	1
Concord Repatriation General Hospital	Concord	Australia	39
Epworth Healthcare	Melbourne	Australia	3
Gachon University	Incheon	South Korea	1
Hackensack University Medical Center	Hackensack	United States	308
Henan Cancer Hospital	Henan	China	1
Inje University Busan-Paik Hospital	Busan	South Korea	1
Liverpool Hospital	Liverpool	Australia	66
Ohio State University	Columbus	United States	169
Pusan National University Hospital	Busan	South Korea	73
Royal Adelaide Hospital	Adelaide	Australia	132
Samsung Medical Center	Seoul	South Korea	1
Seoul National University Hospital	Seoul	South Korea	1
Seoul St. Mary's Hospital	Seoul	South Korea	1
Shanghai East Hospital	Pudong	China	1
Stanford University	Palo Alto	United States	161
University of Michigan	Ann Arbor	United States	538
University of Pittsburgh	Pittsburgh	United States	137
Washington University	St Louis	United States	182

Clinical trials